REASON: Factors influencing outcome in patients (pts) with NSCLC stage IIIB/IV and mutated EGF receptor (EGFR-M+) treated with gefitinib.

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Oncol Res Treat, 39 (suppl 1) (ID 0345), 120. doi:10.1159/000444354

Studie: REASON; Indikation: Bronchialkarzinom; Jahr: 2016; Veranstaltung: DKK; Journal: Oncology Research and Treatment

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com